Price T Rowe Associates Inc. MD Sells 244,061 Shares of Edwards Lifesciences Co. (NYSE:EW)

Price T Rowe Associates Inc. MD cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,297,722 shares of the medical research company's stock after selling 244,061 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.56% of Edwards Lifesciences worth $244,132,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at $26,000. Millstone Evans Group LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Roble Belko & Company Inc bought a new position in Edwards Lifesciences in the 4th quarter worth $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at about $54,000. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,189,770.56. This represents a 16.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock worth $5,163,062 in the last quarter. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on EW shares. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Truist Financial reduced their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Evercore ISI reduced their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $79.45.

Edwards Lifesciences Stock Down 0.4 %

Edwards Lifesciences stock traded down $0.33 during mid-day trading on Thursday, reaching $75.17. The stock had a trading volume of 902,026 shares, compared to its average volume of 4,985,539. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The firm has a market capitalization of $44.19 billion, a PE ratio of 10.78, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock's 50-day simple moving average is $71.03 and its 200-day simple moving average is $71.23.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter in the previous year, the firm earned $0.66 earnings per share. The business's revenue was up 6.2% on a year-over-year basis. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.